Literature DB >> 22161852

Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm.

Mathias Vilaine, Damla Olcaydu, Ashot Harutyunyan, Jonathan Bergeman, Mourad Tiab, Jean-François Ramée, Jian-Min Chen, Robert Kralovics, Sylvie Hermouet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22161852     DOI： 10.1182/blood-2011-08-372813

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?

Authors:  Sylvie Hermouet; Mathias Vilaine
Journal:  Haematologica       Date:  2011-11       Impact factor: 9.941

2.  The relationship of JAK2(V617F) and acquired UPD at chromosome 9p in polycythemia vera.

Authors:  L Wang; S I Swierczek; L Lanikova; S J Kim; K Hickman; K Walker; K Wang; J Drummond; H Doddapaneni; J G Reid; D M Muzny; R A Gibbs; D A Wheeler; J T Prchal
Journal:  Leukemia       Date:  2014-01-27       Impact factor: 11.528

Review 3.  Acquired uniparental disomy of chromosome 9p in hematologic malignancies.

Authors:  Linghua Wang; David A Wheeler; Josef T Prchal
Journal:  Exp Hematol       Date:  2015-12-02       Impact factor: 3.084

Review 4.  Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.

Authors:  Jacob Grinfeld; Jyoti Nangalia; Anthony R Green
Journal:  Haematologica       Date:  2016-12-01       Impact factor: 9.941

Review 5.  The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?

Authors:  Marjorie Boissinot; Mathias Vilaine; Sylvie Hermouet
Journal:  Cancers (Basel)       Date:  2014-08-12       Impact factor: 6.639

Review 6.  Experimental Modeling of Myeloproliferative Neoplasms.

Authors:  Lucie Lanikova; Olga Babosova; Josef T Prchal
Journal:  Genes (Basel)       Date:  2019-10-15       Impact factor: 4.096

7.  The PAX5-JAK2 translocation acts as dual-hit mutation that promotes aggressive B-cell leukemia via nuclear STAT5 activation.

Authors:  Anna S Fedl; Markus Jaritz; Sabine Jurado; Daniela Kostanova-Poliakova; Stephen G Malin; Charles G Mullighan; Sabine Strehl; Maria Fischer; Meinrad Busslinger
Journal:  EMBO J       Date:  2022-02-14       Impact factor: 11.598

8.  PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms.

Authors:  Jelena D Milosevic Feenstra; Roland Jäger; Fiorella Schischlik; Daniel Ivanov; Gregor Eisenwort; Elisa Rumi; Michael Schuster; Bettina Gisslinger; Sigrid Machherndl-Spandl; Peter Bettelheim; Maria-Theresa Krauth; Felix Keil; Christoph Bock; Mario Cazzola; Heinz Gisslinger; Robert Kralovics; Peter Valent
Journal:  Am J Hematol       Date:  2022-01-21       Impact factor: 13.265

9.  Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms.

Authors:  Hye-Ran Kim; Hyun-Jung Choi; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Jong-Hee Shin; Soon-Pal Suh; Dong-Wook Ryang; Myung-Geun Shin
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

Review 10.  Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation.

Authors:  Sylvie Hermouet; Edith Bigot-Corbel; Betty Gardie
Journal:  Mediators Inflamm       Date:  2015-10-11       Impact factor: 4.711
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.